These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16281444)

  • 1. [Community-acquired pneumonia: attitude case of treatment failure].
    Genné D; Rakotoarimanana R
    Rev Med Suisse; 2005 Oct; 1(36):2333-4, 2336-7. PubMed ID: 16281444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia.
    Rosón B; Carratalà J; Fernández-Sabé N; Tubau F; Manresa F; Gudiol F
    Arch Intern Med; 2004 Mar; 164(5):502-8. PubMed ID: 15006826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. At the threshold: defining clinically meaningful resistance thresholds for antibiotic choice in community-acquired pneumonia.
    Daneman N; Low DE; McGeer A; Green KA; Fisman DN
    Clin Infect Dis; 2008 Apr; 46(8):1131-8. PubMed ID: 18444846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia.
    Frei CR; Restrepo MI; Mortensen EM; Burgess DS
    Am J Med; 2006 Oct; 119(10):865-71. PubMed ID: 17000218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome.
    Menéndez R; Torres A; Zalacaín R; Aspa J; Martín Villasclaras JJ; Borderías L; Benítez Moya JM; Ruiz-Manzano J; Rodríguez de Castro F; Blanquer J; Pérez D; Puzo C; Sánchez Gascón F; Gallardo J; Alvarez C; Molinos L;
    Thorax; 2004 Nov; 59(11):960-5. PubMed ID: 15516472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonresponses and treatment failures with conventional empiric regimens in patients with community-acquired pneumonia.
    Tan JS
    Infect Dis Clin North Am; 2004 Dec; 18(4):883-97. PubMed ID: 15555830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early and late treatment failure in community-acquired pneumonia.
    Garcia-Vidal C; Carratalà J
    Semin Respir Crit Care Med; 2009 Apr; 30(2):154-60. PubMed ID: 19296415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors and outcome of community-acquired pneumonia due to Gram-negative bacilli.
    Falguera M; Carratalà J; Ruiz-Gonzalez A; Garcia-Vidal C; Gazquez I; Dorca J; Gudiol F; Porcel JM
    Respirology; 2009 Jan; 14(1):105-11. PubMed ID: 18699803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Basis and guidelines for empirical antibody therapy in the management of community-acquired pneumonia].
    Louzir B; Beji M; Fajraoui N; Mehiri N; Daghfous J
    Tunis Med; 2001 Oct; 79(10):491-7. PubMed ID: 11910687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Optimizing the antibiotics policy in The Netherlands. VIII. Revised SWAB guidelines for antimicrobial therapy in adults with community-acquired pneumonia].
    Schouten JA; Prins JM; Bonten M; Degener JE; Janknegt R; Hollander JM; Jonkers R; Wijnands W; Verheij T; Sachs A; Kullberg BJ
    Ned Tijdschr Geneeskd; 2005 Nov; 149(45):2495-500. PubMed ID: 16304886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic therapy and 48-hour mortality for patients with pneumonia.
    Mortensen EM; Restrepo MI; Anzueto A; Pugh JA
    Am J Med; 2006 Oct; 119(10):859-64. PubMed ID: 17000217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Community-acquired pneumonia in adults].
    Chidiac C; Ader F
    Rev Prat; 2011 Oct; 61(8):1077-84. PubMed ID: 22135972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe community-acquired pneumonia: an Australian perspective.
    Wilson PA; Ferguson J
    Intern Med J; 2005 Dec; 35(12):699-705. PubMed ID: 16313544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antibiotic therapy for community acquired Streptococcus pneumoniae pneumonia: clinical relevance of antibiotic resistance].
    Bédos JP; Bruneel F
    Med Mal Infect; 2006; 36(11-12):667-79. PubMed ID: 16842956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [What is new in the treatment of community-acquired pneumonia?].
    Welte T; Marre R; Suttorp N;
    Med Klin (Munich); 2006 Apr; 101(4):313-20. PubMed ID: 16607488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-terminal provasopressin (copeptin) in patients with community-acquired pneumonia--influence of antibiotic pre-treatment: results from the German competence network CAPNETZ.
    Krüger S; Ewig S; Kunde J; Hanschmann A; Marre R; Suttorp N; Welte T;
    J Antimicrob Chemother; 2009 Jul; 64(1):159-62. PubMed ID: 19403654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia.
    Peralta G; Sánchez MB; Garrido JC; De Benito I; Cano ME; Martínez-Martínez L; Roiz MP
    J Antimicrob Chemother; 2007 Oct; 60(4):855-63. PubMed ID: 17644532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Community-acquired pneumonia in children].
    Gendrel D; Moulin F
    Rev Prat; 2007 Nov; 57(17):1883-94. PubMed ID: 18095624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Community-acquired pneumonia: what is relevant and what is not?
    Talwar A; Lee H; Fein A
    Curr Opin Pulm Med; 2007 May; 13(3):177-85. PubMed ID: 17414124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moxifloxacin versus standard therapy in patients with pneumonia hospitalized after failure of preclinical anti-infective treatment.
    Wenisch C; Krause R; Széll M; Laferl H
    Infection; 2006 Aug; 34(4):190-5. PubMed ID: 16896576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.